Registration 333-290955
S-1/A · 2026-09-18 · 0001213900-26-101489
Terms from the governing filing for this registration; not a claim that the offering is open today.
Company research
CIK 2061622Updated Oct 6, 2026
1 filing on record · S-1/A.
21Shares Injective ETF (the “Trust”) is an exchange-traded fund that issues common shares of beneficial interest (the “Shares”) that are expected to trade on the Nasdaq Stock Market LLC (the “Exchange”). The Trust’s investment objective is to seek to track the performance of INJ, as measured by the performance of the FTSE Injective Index (the “Pricing Benchmark”), as adjusted for the Trust’s expenses and other liabilities, and to reflect rewards from staking a portion of the Trust’s INJ, to the extent the Sponsor in its sole discretion determines that the Trust may do so without undue legal or regulatory risk, such as, without limitation, the risk of jeopardizing the Trust’s ability to qualify as a grantor trust for tax purposes. The Pricing Benchmark is calculated by FTSE International Limited (the “Benchmark Provider” or “FTSE”). The Pricing Benchmark is designed to track the performance of INJ in U.S. dollars. The Shares of the Trust are valued daily based on the Pricing Benchmark.